The press release confirms continued dose-escalation and tolerability across all programs but provides no new decisive efficacy readout. ASCO posters in late May may provide incremental detail, but the material catalyst remains the next formal data update expected in late 2026. No immediate trading catalyst from this filing alone.
Price Chart
Executive Summary
Perspective Therapeutics announced it will present updated data on three clinical-stage programs ([²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, [²¹²Pb]PSV359) at ASCO 2026. The updates confirm previously disclosed response rates and safety profiles — no transformative new efficacy signal was introduced. The disclosure is procedural (conference presentation), not a material event that changes the investment thesis.
Key Facts
- Data for [212Pb]VMT-α-NET (n=25 efficacy, n=68 safety) consistent with prior AACR disclosures; deepening responses observed with ~6 weeks additional follow-up
- [212Pb]VMT01 melanoma cohort: 2 confirmed responses out of 7 (29%) in 3.0 mCi monotherapy; 6/7 (86%) with stable disease or partial response
- [212Pb]PSV359 advanced to Cohort 3 (6.0 mCi) with no DLTs; Grade 1-2 TEAEs only
- ASCO presentations scheduled May 30-31, 2026; further data across all programs expected in late 2026
- [212Pb]VMT01 has FDA Fast Track Designation (granted Sep 2024)
Financial Impact
No financial data reported; pre-revenue clinical-stage biotech with no current product sales or guidance
Risk Factors
- Phase 1/2a data remain early-stage; no registrational trial initiation yet announced
- Response rates in VMT01 (29% in monotherapy) are modest; combination with nivolumab cohort (n=6) data immature
- VMT-α-NET competition from established approved therapies (Lutathera, F-177Lu edotreotide) with proven OS data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299819 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.28 | awaiting T+20 | — | $1.15 (−49.34%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.15 (−57.38%) |
Oct 2, 2026 23d ago | Press Release | $2.76 | awaiting T+20 | — | $1.15 (−58.15%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.15 (−60.45%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.15 (−58.90%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.15 (−61.37%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.15 (−62.98%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.15 (−62.98%) |
Aug 10, 2026 10w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.15 (−63.68%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.15 (−61.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers